Vistagen shares plummeted 82% after its Phase 3 PALISADE-3 trial revealed fasedienol failed to outperform placebo in reducing public speaking anxiety. Following the setback, Lucid Capital downgraded the stock to Neutral and lowered its price target to $1, triggering a sharp sell-off and significant investor losses.